

Artemisinin and the Nobel Prize in physiology or medicine 2015

Jong Yeon Park

Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

In this issue of the Korean Journal of Pain, an experimental research paper about the antinociceptive effect of Artemisinin is presented [1].

Artemisinin and its semisynthetic derivatives are a group of medicines used to treat malaria due to *Plasmodium falciparum* [2]. Artemisia plants include about 300 species worldwide, and are distributed in temperate, warm temperate, and subtropical regions, mainly in Asia, Europe, and North Africa. In Korea, it is known as Annual Wormwood.

Scientists worldwide had screened over 240,000 compounds against malaria, but the search ended in failure. In 1969, Tu Youyou, a Chinese pharmaceutical chemist and educator, had the idea of screening Chinese herbs. She first investigated the historical Chinese medical classics, and visited practitioners of traditional Chinese medicine all over the country on her own. She gathered her findings in a notebook called “A Collection of Single Practical Prescriptions for Anti-Malaria”. Her notebook summarized 640 prescriptions. By 1971, her team had screened over 2,000 traditional Chinese recipes and made 380 herbal extracts, from some 200 herbs, which were tested on mice.

Tu discovered Artemisinin and its derivatives were discovered in 1972. Her discovery of artemisinin and dihydroartemisinin was a significant breakthrough in 20th

century tropical medicine, saving millions of lives in South China, Southeast Asia, Africa, and South America. For her dedication to Artemisinin, she was awarded half of the 2015 Nobel Prize in medicine. Tu is the first Chinese Nobel laureate in physiology or medicine and the first female citizen of the People’s Republic of China to receive a Nobel Prize in any category.

Interestingly, it is known that Artemisinin and its derivatives (artemisinins) might have a therapeutic value for several other diseases beyond malaria, including cancers, inflammatory diseases, and autoimmune disorders. Recently discovered properties of artemisinins suggested that they might be used to treat neurodegenerative disorders by decreasing oxidation, inflammation, and amyloid beta protein [3].

Especially, in this issue, the authors used the writhing test as an inflammatory pain model, and they suggested that antinociceptive effects of artemisinin are mediated by GABA_A receptors. We need to further investigate the antinociceptive or anti-inflammatory effect of Artemisinin.

We find many traditional plants and natural products all around us. If we make the extra effort to investigate novel substances, we could be the ones to discover new strategies and drugs for management of pain in the future.

Received June 4, 2019. Accepted June 4, 2019.

Correspondence to: Jong Yeon Park

Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea

Tel: +82-2-3010-3867, Fax: +82-2-3010-6958, E-mail: jongyeon_park@amc.seoul.kr

ORCID: <https://orcid.org/0000-0003-0588-1903>

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

© The Korean Pain Society, 2019

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Dehkordi FM, Kaboutari J, Zendejdel M, Javdani M. The antinociceptive effect of Artemisinin on the inflammatory pain and role of GABAergic & opioidergic systems. *Korean J Pain* 2019; 32: 160–7.
2. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents Chemother* 1997; 41: 1413–22.
3. Lu BW, Baum L, So KF, Chiu K, Xie LK. More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration. *Neural Regen Res* 2019; 14: 1494–8.